Cargando…

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial

This multi-center, randomized, double-blind, placebo-controlled, two-way crossover study was designed to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of single and once-daily repeat doses of vilanterol 25 µg in children aged 5–11 years. Twenty-eight children wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oliver, Amanda, VanBuren, Sandi, Allen, Ann, Hamilton, Melanie, Tombs, Lee, Kempsford, Rodger, Qaqundah, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467260/ https://www.ncbi.nlm.nih.gov/pubmed/26097789 http://dx.doi.org/10.1002/cpdd.92

Ejemplares similares

Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
por: Chen, Xia, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects
por: Allen, Ann, et al.
Publicado: (2014)

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects
por: Kempsford, Rodger, et al.
Publicado: (2014)

Comparison of vilanterol, a novel long-acting beta(2) agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids
por: Lötvall, Jan, et al.
Publicado: (2014)

Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial
por: Bardsley, George, et al.
Publicado: (2018)

Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy
por: Oliver, Amanda J., et al.
Publicado: (2016)

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial
por: Kelleher, Dennis L., et al.
Publicado: (2012)

Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease
por: Siederer, Sarah, et al.
Publicado: (2015)

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
por: O’Byrne, Paul M., et al.
Publicado: (2014)

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
por: Umeda, Akira, et al.
Publicado: (2023)

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD
por: Mehta, Rashmi, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
por: Breuer, C., et al.
Publicado: (2013)

Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study
por: Mehta, Rashmi, et al.
Publicado: (2014)

Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the US
por: Bogart, Michael, et al.
Publicado: (2023)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Applying the Risk of Bias Tool in a Systematic Review of Combination Long-Acting Beta-Agonists and Inhaled Corticosteroids for Persistent Asthma
por: Hartling, Lisa, et al.
Publicado: (2011)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β(2)-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England
por: Czira, Alexandrosz, et al.
Publicado: (2023)

In Vitro Drug Delivery of a Fixed-Dose Combination of Fluticasone Furoate/Umeclidinium/Vilanterol from a Dry Powder Inhaler
por: Hamilton, Melanie, et al.
Publicado: (2023)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Budget Impact Analysis of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma in the Dubai Academic Healthcare Corporation
por: Hamouda, Mohamed, et al.
Publicado: (2023)

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
por: Singh, Dave, et al.
Publicado: (2016)

Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial
por: Hu, Chaoying, et al.
Publicado: (2015)

Inhaled milrinone in cardiac surgical patients: pharmacokinetic and pharmacodynamic exploration
por: Nguyen, Anne Quynh-Nhu, et al.
Publicado: (2023)

New combination treatments in the management of asthma: focus on fluticasone/vilanterol
por: Tan, Laren D, et al.
Publicado: (2014)

Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol
por: Albertson, Timothy E, et al.
Publicado: (2015)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
por: Albertson, Timothy E, et al.
Publicado: (2019)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
por: Bremner, Peter R., et al.
Publicado: (2018)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
por: Maltais, François, et al.
Publicado: (2019)

Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome
por: Lee, Suh-Young, et al.
Publicado: (2016)

Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United States
por: Averell, Carlyne M., et al.
Publicado: (2022)

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
por: Busse, William W, et al.
Publicado: (2013)

A Rare Presentation of Drug-induced Liver Injury with Fluticasone and Vilanterol Inhaler Use
por: Rishi, Mohit, et al.
Publicado: (2019)

Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study
por: Riley, John H., et al.
Publicado: (2018)

Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β(2)-adrenoreceptor agonist (uLABA)
por: Bjermer, Leif, et al.
Publicado: (2015)

Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial
por: Daley-Yates, Peter, et al.
Publicado: (2022)

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
por: Brealey, Noushin, et al.
Publicado: (2015)

Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
Publicado: (2016)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
por: Wang, B, et al.
Publicado: (2017)

RETRACTED ARTICLE: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2008)

Comment on: “Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists”
por: Samuelsen, Carl, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uoivhks7i4tur5e33h39c9ub9n